A detailed history of Deutsche Bank Ag\ transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 766,544 shares of VERA stock, worth $35.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
766,544
Previous 635,360 20.65%
Holding current value
$35.1 Million
Previous $23 Million 47.36%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$34.09 - $46.71 $4.47 Million - $6.13 Million
131,184 Added 20.65%
766,544 $33.9 Million
Q2 2024

Aug 14, 2024

SELL
$33.72 - $48.82 $55,098 - $79,771
-1,634 Reduced 0.26%
635,360 $23 Million
Q1 2024

May 15, 2024

BUY
$14.91 - $49.14 $49,337 - $162,604
3,309 Added 0.52%
636,994 $27.5 Million
Q4 2023

Feb 14, 2024

BUY
$9.29 - $16.0 $5.74 Million - $9.88 Million
617,654 Added 3852.87%
633,685 $9.75 Million
Q3 2023

Nov 09, 2023

BUY
$13.71 - $19.64 $31,382 - $44,955
2,289 Added 16.66%
16,031 $219,000
Q2 2023

Aug 14, 2023

SELL
$6.11 - $17.83 $1,270 - $3,708
-208 Reduced 1.49%
13,742 $220,000
Q1 2023

May 15, 2023

BUY
$5.41 - $18.3 $41,126 - $139,116
7,602 Added 119.75%
13,950 $108,000
Q4 2022

Feb 13, 2023

BUY
$15.74 - $22.19 $1,448 - $2,041
92 Added 1.47%
6,348 $122,000
Q3 2022

Nov 14, 2022

SELL
$13.27 - $22.31 $30,746 - $51,692
-2,317 Reduced 27.03%
6,256 $133,000
Q2 2022

Aug 11, 2022

BUY
$12.82 - $23.4 $6,012 - $10,974
469 Added 5.79%
8,573 $116,000
Q1 2022

May 13, 2022

BUY
$17.8 - $28.06 $37,219 - $58,673
2,091 Added 34.77%
8,104 $191,000
Q4 2021

Feb 11, 2022

BUY
$15.01 - $35.8 $29,194 - $69,631
1,945 Added 47.81%
6,013 $161,000
Q3 2021

Nov 04, 2021

BUY
$13.71 - $30.6 $55,772 - $124,480
4,068 New
4,068 $71,000

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $1.24B
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.